A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Kite Pharma
Protocol Number
KTE-C19-101
Cancer Diagnosis
To Learn More Call
201-510-0910